= 25 nM). Exhibits >1,200-fold selectivity for LPA1
. Attenuates NHLF human lung fibroblast cell proliferation and contraction in vitro
. Also reduces plasma histamine levels in mouse LPA-challenge model. Orally bioavailable.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Discovery of highly selective and orally active lysophosphatidic acid receptor-1 antagonists with potent activity on human lung fibroblasts.
Qian et al.